Institut Català de la Salut
[Zamora M] BCNatal, Fetal Medicine Research Center, Barcelona, Spain. Hospital Clínic, Barcelona, Spain. Hospital Sant Joan de Déu, Barcelona, Spain. Universat de Barcelona, Barcelona, Spain. Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. [Villena JA] Laboratori de Metabolisme i Obesitat, Vall d’Hebron Institut de Recerca, Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Spain. CIBERDEM, CIBER on Diabetes and Associated Metabolic Diseases, Instituto de Salud Carlos III, Madrid, Spain
Vall d'Hebron Barcelona Hospital Campus
2019-07-19T08:38:54Z
2019-07-19T08:38:54Z
2019-06-11
Diabetes; Diabetic cardiomyopathy; Heart
Diabetis; Cardiomiopatia diabètica; Cor
Diabetes; Cardiomiopatía diabética; Corazón
Diabetic cardiomyopathy (DCM) has emerged as a relevant cause of heart failure among the diabetic population. Defined as a cardiac dysfunction that develops in diabetic patients independently of other major cardiovascular risks factors, such as high blood pressure and coronary artery disease, the underlying cause of DCMremains to be unveiled. Several pathogenic factors, including glucose and lipid toxicity, mitochondrial dysfunction, increased oxidative stress, sustained activation of the renin-angiotensin system (RAS) or altered calcium homeostasis, have been shown to contribute to the structural and functional alterations that characterize diabetic hearts. However, all these pathogenic mechanisms appear to stem from the metabolic inflexibility imposed by insulin resistance or lack of insulin signaling. This results in absolute reliance on fatty acids for the synthesis of ATP and impairment of glucose oxidation. Glucose is then rerouted to other metabolic pathways, with harmful effects on cardiomyocyte function. Here, we discuss the role that impaired cardiac insulin signaling in diabetic or insulin-resistant individuals plays in the onset and progression of DCM.
Supported by grants BFU2015-64462R from the Ministerio de Economía y Competitividad (MINECO/FEDER, UE) and HR17-00627 from La Caixa Foundation to J.A.V.
Artículo
Versión publicada
Inglés
Diabetis - Complicacions; Cor - Malalties; Insulinoresistència; Síndrome metabòlica; DISEASES::Cardiovascular Diseases::Heart Diseases::Cardiomyopathies::Diabetic Cardiomyopathies; Other subheadings::Other subheadings::Other subheadings::/physiopathology; DISEASES::Nutritional and Metabolic Diseases::Metabolic Diseases::Glucose Metabolism Disorders::Hyperinsulinism::Insulin Resistance; DISEASES::Nutritional and Metabolic Diseases::Metabolic Diseases::Nutritional and Metabolic Diseases::Metabolic Diseases::Metabolic Syndrome; Other subheadings::Other subheadings::Other subheadings::/complications; ENFERMEDADES::enfermedades cardiovasculares::enfermedades cardíacas::miocardiopatías::miocardiopatías diabéticas; Otros calificadores::Otros calificadores::Otros calificadores::/fisiopatología; ENFERMEDADES::enfermedades nutricionales y metabólicas::enfermedades metabólicas::trastornos del metabolismo de la glucosa::hiperinsulinismo::resistencia a la insulina; ENFERMEDADES::enfermedades nutricionales y metabólicas::enfermedades metabólicas::enfermedades nutricionales y metabólicas::enfermedades metabólicas::síndrome metabólico; Otros calificadores::Otros calificadores::Otros calificadores::/complicaciones
MDPI
International Journal of Molecular Sciences;20(11)
https://www.mdpi.com/1422-0067/20/11/2833
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
Articles científics - VHIR [1655]